An observational study in Autoimmune Diseases and Advanced Cancer, sponsored by University Hospital, Brest. Completed at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-22.
Sponsored by University Hospital, Brest · Observational
The tolerance of immune checkpoint inhibitors is unknown in patients with pre-existing autoimmune conditions. This retrospective nation-wide study will assess their tolerance in patients with pre-existing autoimmune conditions who received immune checkpoint inhibitors for an advanced cancer in clinical practice.
655 studies on the registry are indexed under Autoimmune Diseases; 275 are open to participants now.
This study's enrollment of 112 is below the median of 300 across 208 observational studies indexed under Autoimmune Diseases.
Browse Autoimmune Diseases studies →University Hospital, Brest is the lead sponsor of 594 studies on the registry; 135 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with a pre-existing autoimmune disease who received immune checkpoint inhibitors for the treatment of an advanced cancer in clinical practice.
Exclusion Criteria:
Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice
Autoimmune disease flare
Increase in the activity of the pre-existing autoimmune disease as assessed by the treating physician
Time frame: through study completion, an average of 1 year
Other immune/inflammatory complications
Development of a new immune/inflammatory condition after the start of the therapy
Time frame: through study completion, an average of 1 year
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Brest